Mass photometry is an analytical technique used to investigate biomolecules at the single-particle level. It is able to analyze these particles in their native state and without the need for labels.

Automated mass photometry combines the unparalleled simplicity and sensitivity of Refeyn’s molecular mass measurement technology with the efficiency and ease of automation. This approach offers ...

Mass photometry is a novel bioanalytical technology that provides insights into the mass distribution of biomolecules in their native state within minutes, without the need for labeling, surface ...

High quality samples are key for data reproducibility and reliability. For biophysical protein characterization, quality samples are defined as those containing pure, soluble protein exhibiting ...

Refeyn has announced that mass photometry has been recognized by the US Pharmacopeia (USP) – and referenced in the new draft USP general chapter <1067> – as a key orthogonal method for characterizing ...

Protein oligomerization is central to many cellular processes; however, capturing and characterizing native protein behaviors in solution can be challenging. Mass photometry is especially suited for ...

A recently-developed technique for measuring the mass of single molecules in solution has the potential to help companies using adeno-associated viruses (AAV) as a vector for gene therapies. That’s ...

CRISPR-Cas systems are widely used in genome engineering applications. They contain RNA-guided ribonucleoprotein (RNP) complexes that selectively modify DNA sequences at any specific location in the ...

To permanently access this eBook for free, fill out the short form below. Struggling with AAV and AdV vector analytical characterization and analysis? Mass photometry and macro mass photometry offer ...

Biochemical and structural studies of membrane proteins have long been restricted to their isolated soluble domains. This limitation has prevented the study of complexes involving full-length membrane ...

Precision oncology company Orakl Oncology (Villejuif, France) has raised €11 million in seed funding to enable it to begin marketing its first two AI-powered products for oncology drug development, ...